SemaglutideRx
GLP-1 Receptor Agonist

SemaglutideRx
GLP-1 Receptor Agonist
TirzepatideRx
Dual GLP-1 + GIP Receptor Agonist
Semaglutide ODT PillsRx
GLP-1 Receptor Agonist - Oral Dissolving Tablet
Tirzepatide ODT PillsRx
Dual GLP-1 + GIP Receptor Agonist - Oral Dissolving Tablet
Men's Complete Hair Growth PillRx
Minoxidil, Finasteride, Biotin
Men's Advanced Hair SprayRx
Minoxidil, Finasteride, Fluocinolone, Tretinoin
Women's Premium Hair SprayRx
Minoxidil, Tretinoin, Fluocinolone, Biotin, Melatonin
Women's Complete Hair Growth PillRx
Minoxidil, Vitamin E, Biotin
Written by Join Luma Team
November 8, 2026 · 8 min read

You may not be losing weight on tirzepatide because you are still titrating, need more time, or have factors masking or limiting progress.
A slow start is information to review with your Join Luma clinician, not a reason to double your dose or blame yourself.
Reason 1 is that you are still titrating. The Zepbound label starts at 2.5 mg weekly for four weeks; this is an initiation dose, not a maintenance dose. The first labeled maintenance option is 5 mg weekly. Further increases, if prescribed, follow at least four weeks at the current dose. Someone early in this process has not yet had the same exposure as a trial participant followed for more than a year.
Bring your actual dose history to your clinician: milligrams, dates and time at each step. Do not judge effectiveness by how many syringe units you use, since units depend on concentration. The tirzepatide dosing schedule explains the brand framework, while your own clinician determines whether a change is appropriate.
Reason 2 is timeline expectations. Appetite and scale weight do not always change together, and progress is not a straight line. There is no reliable promise that a particular week will deliver a specific number of pounds. A review should consider the whole treatment interval, not the difference between yesterday and today.
In SURMOUNT-1, Jastreboff and colleagues studied 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes. The 72-week trial included a 20-week escalation period. It tested branded tirzepatide, the medicine approved as Zepbound for weight management and Mounjaro for diabetes, not compounded preparations. The NEJM trial report provides the following treatment-regimen averages.
| Study group | Mean reduction from baseline |
|---|---|
| Tirzepatide 5 mg weekly | 15.0% |
| Tirzepatide 10 mg weekly | 19.5% |
| Tirzepatide 15 mg weekly | 20.9% |
| Placebo | 3.1% |
These are group averages over 72 weeks, not minimum results or monthly targets. Different starting health profiles, treatment interruptions and individual responses can change outcomes. The table does not show that increasing your dose without review will reproduce a trial average. It gives a useful long-term reference for a conversation about benefit and tolerability.
Reason 3 is ordinary scale fluctuation. Fluid retention, salty meals, menstrual-cycle changes and bowel contents can affect a weigh-in. Constipation can also make the scale temporarily less informative. A brief rise does not establish that fat mass increased, and a rapid drop is not necessarily all fat loss.
If weighing is useful and not distressing, use comparable conditions: the same scale, a similar time and similar clothing. Look at a trend across several weeks rather than chasing daily changes. Waist measurements, how clothing fits and physical function can add context, although none independently proves that a medication is working. Tell your clinician if swelling or sudden unexplained weight change accompanies new symptoms.
Reason 4 is eating patterns, including liquid calories. Smaller meals can coexist with frequent grazing, alcohol, sweetened coffee or other drinks that add substantial energy. This is not about labeling foods as good or bad. A short, nonjudgmental record of meals, drinks, hunger and meal timing can help identify one realistic adjustment rather than starting an extreme diet.
Reason 5 is protein and muscle support. Eating very little can make it difficult to get enough protein and other nutrients or maintain strength. Muscle matters for function and long-term health; its preservation deserves attention even when the scale is moving. Ask your clinician about a practical protein target and resistance exercise suited to your health, rather than assuming more restriction is always better.
The protein planning calculator can help organize questions, but medical conditions such as kidney disease may require individualized advice.
Reason 6 is sleep and stress. Irregular sleep, shift work or sustained stress can make hunger management, meal planning and activity harder. These factors are not personal failings. Choose one workable action, such as a consistent wind-down routine or preparing an easy meal before a demanding workday. Tell your clinician about loud snoring, daytime sleepiness or other concerns that may warrant evaluation.
Reason 7 is another medication or health issue. Some medicines, including certain steroids, psychiatric medicines and diabetes treatments, can promote weight gain. Your clinician needs a complete list, including recent changes, over-the-counter products and supplements. Do not stop a needed medicine to improve your weight trend; there may be safer alternatives or another explanation worth checking.
NIDDK discusses individualized medication treatment. A thoughtful review can separate a medication-response question from practical barriers or a medical problem that deserves its own care.
Same price every dose
A licensed provider reviews your intake. If treatment is appropriate, your medication ships free with expedited two-day delivery.
Get startedReason 8 is inconsistent exposure: missed injections, uncertain technique, a storage problem or confusion about concentration. Review the pharmacy label and beyond-use date. A brand pen’s room-temperature allowance does not establish how long a compounded vial can be stored. If directions are unclear or you think an injection was incomplete, ask before repeating it.
Bring the medication label or a clear photo, your last injection date and the dates of any missed doses. Never compensate by taking extra. The concentration and units guide can help you describe what you have, without turning the review into a do-it-yourself dose conversion.
“Talk to your doctor if you have questions about your medicines.”
The FDA-approved brand injection schedules discussed here are reference information, not a prescription for a compounded formulation. Join Luma offers compounded medications, which are not FDA-approved and were not the products studied in brand clinical trials. Their dose, concentration, directions and beyond-use date must come from your own prescription label and clinician. The FDA explains these distinctions.
Send a concise summary: starting weight, recent trend, weeks at each dose, appetite changes, side effects, meals, activity, sleep and missed injections. Ask whether the treatment has had enough time, whether the prescription remains appropriate and whether another health condition or medication should be reviewed. Your clinician may recommend continuing, adjusting the plan or considering another approach.
Choose one or two sustainable actions while awaiting routine guidance. For example, keep consistent injection records and plan a reliable protein-containing breakfast. More drastic restriction or a higher unapproved dose can create new problems without answering the original question. The weight-loss plateau guide offers another way to organize a longer-term review.
Seek urgent care for severe or persistent abdominal pain, repeated vomiting with dehydration, or other severe symptoms. Call 911 for trouble breathing, swelling of the face or throat, or another potentially life-threatening allergic reaction. Routine scheduling questions belong with your clinician, but serious symptoms should not wait for a portal reply. Tell the clinician about pregnancy plans, diabetes medicines and planned procedures before making treatment changes.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality before marketing. Brand-product study results describe the FDA-approved products studied. A licensed clinician decides whether treatment is appropriate; follow your prescription label and your clinician's directions.
This article is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Individual treatment decisions should be made with a licensed healthcare provider.
Not necessarily. Zepbound starts with an initiation dose, and meaningful assessment requires your dose history, time on treatment and overall response.
No. Your Join Luma clinician should review response and tolerability before any prescription change.
At 72 weeks, mean reductions were 15.0%, 19.5% and 20.9% with branded tirzepatide 5, 10 and 15 mg weekly, respectively. These are not guaranteed individual or compounded-product outcomes.
Bowel contents can affect scale weight and make a short interval harder to interpret. Persistent or severe constipation should be discussed with your clinician.
No. Nausea is a side effect, not a required marker of benefit or a reason to increase medication.
Send your weight trend, exact prescribed dose, weeks at that dose, side effects and missed injections. Include other medication changes and any label or storage questions.
Share this article